Intensified Monitoring of PhArmacology of Cabozantinib as a Tool for Toxicity Management in Patients With Renal Cell Carcinoma

Ki vehet részt

• Patients diagnosed with histologically confirmed advanced/metastatic RCC with predominantly clear cell subtype
• Advanced (not amenable to curative surgery or radiation therapy) or metastatic (AJCC Stage IV) RCC, candidate to receive systemic treatment with nivolumab + Cabozantinib or Cabozantinib monotherapy as per clinical practice (investigators choice)
• Signed Written Informed Consent
• Male or female subjects aged ≥18 years old
• Women of childbearing potential must avoid pregnancy while on Cabozantinib. Female partners of male patients taking Cabozantinib must also avoid pregnancy. Effective methods of contraception should be used by male and female patients and their partners during therapy, and for at least 4 months after completing therapy. Because oral contraceptives might possibly not be considered as "effective methods of contraception", due to factors such as missed doses, gastrointestinal disturbances, or potential drug interactions that could reduce their effectiveness, they should be used together with another method, such as a barrier method
• Previous nephrectomy is permitted
• All IMDC (International Metastatic RCC Database Consortium) risk (good, intermediate, poor)
• Eastern Cooperative Oncology Group performance status 0 or 1
• Capable of understanding and complying with the protocol requirements
• patients will be included in the study regardless of their time of treatment start with Cabozantinib and regardless of their concomitant diseases or co-medication
• Patients diagnosed with histologically confirmed advanced/metastatic RCC with predominantly clear cell subtype
• Advanced (not amenable to curative surgery or radiation therapy) or metastatic (AJCC Stage IV) RCC, candidate to receive systemic treatment with nivolumab + Cabozantinib or Cabozantinib monotherapy as per clinical practice (investigators choice)

Ki nem vehet részt

• Diagnosis of any non-RCC malignancy occurring within 2 years prior to the date of the start of treatment except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or of the cervix or low-grade prostate cancer (≤pT2, N0; Gleason 6) with no plans for treatment intervention
• Diagnosis of any non-RCC malignancy occurring within 2 years prior to the date of the start of treatment except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or of the cervix or low-grade prostate cancer (≤pT2, N0; Gleason 6) with no plans for treatment intervention
• Any condition that, in the investigator's judgment, could compromise appropriate participation in the study
• Patients with non-renal cell neoplasms of the kidney (e.g. urothelial, sarcoma, lymphoma)
• Pregnancy status
• Refusal of informed consent
• Patients who could not attend periodic clinical check-ups
• Patients with non-renal cell neoplasms of the kidney (e.g. urothelial, sarcoma, lymphoma)